Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 08, 2022 16:30 ET | Source: MeiraGTx

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

LONDON and NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a...
November 22, 2022 16:30 ET | Source: MeiraGTx

MeiraGTx to Participate in Upcoming Investor Conferences

LONDON and NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria...
November 10, 2022 08:00 ET | Source: MeiraGTx

MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.

-- Updated Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Now Dosing Patients in Phase 1 Trial...
October 04, 2022 08:00 ET | Source: MeiraGTx

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

LONDON and NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company will...
October 01, 2022 10:00 ET | Source: MeiraGTx

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

LONDON and NEW YORK, Oct. 01, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq:MGTX), a vertically integrated, clinical-stage gene therapy company, announced today the primary...
September 16, 2022 02:00 ET | Source: MeiraGTx

MeiraGTx’s Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

-- Manufacturing facilities built to accelerate development and delivery of advanced medicines to patients using state-of-the-art technology at scale, with quality appropriate for commercialization ...
September 08, 2022 16:30 ET | Source: MeiraGTx

MeiraGTx to Participate in Upcoming Investor Conferences

LONDON and NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria...
August 11, 2022 08:30 ET | Source: MeiraGTx

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

-- Recent Positive Topline Data from the Phase 1/2 Trial of Botaretigene Sparoparvovec (AAV-RPGR) for the Treatment of X-linked Retinitis Pigmentosa (XLRP) -- Financing Secured by Manufacturing...
August 03, 2022 08:00 ET | Source: MeiraGTx

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

- Credit facility is collateralized by MeiraGTx’s wholly-owned manufacturing facilities in London, UK and Shannon, Ireland - $75 million at closing strengthens balance sheet and extends runway to...
June 28, 2022 07:00 ET | Source: MeiraGTx

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to Untreated Randomized Control

• The primary outcome of the MGT009 study is safety, and botaretigene sparoparvovec treatment was found to be generally safe and well-tolerated • Significant improvements were demonstrated in...